Center for Research in Medical Pharmacology, University of Insubria, Via Ottorino Rossi n.9, 21100, Varese VA, Italy,
Inflamm Res. 2015 Feb;64(2):127-35. doi: 10.1007/s00011-014-0791-8. Epub 2015 Jan 6.
Adrenergic modulation of immunity has been extensively characterized, however, few information exist regarding polymorphonuclear leukocytes (PMN), despite their key role in immunity and inflammation. We investigated the effect of adrenergic agents on human PMN migration, CD11b and CD18 expression, reactive oxygen species (ROS) and interleukin (IL)-8 production, and on adrenoceptor (AR) expression.
Migration was measured by the Boyden chamber assay, CD11b/CD18 expression was assessed by flow cytometry, intracellular ROS were detected by spectrofluorimetry, and IL-8 was quantitated by standard ELISA assay. AR mRNA levels were measured by real-time PCR and PMN morphology was studied by scanning electron microscopy.
Adrenaline(A), noradrenaline and the β-AR agonist isoprenaline reduced N-formyl-Met-Leu-Phe (fMLP)-induced migration, CD11b/CD18 expression, and ROS production, without affecting IL-8. The effect of A on CD11b was antagonized by yohimbine and propranolol, and increased by prazosin. The effect on ROS production was completely abolished by propranolol. PMN expressed α(1A)-, α(1B)-, α(1D)-, α(2A)-, α(2C)-, β(1)-, β(2)-, and β(3)-AR mRNA. A prevented fMLP-induced morphological changes of PMN.
Adrenergic agents reduced PMN responses mainly through β-AR, although α-AR may contribute at least to CD11b expression. AR-operated pathways in PMN should be investigated in disease conditions and in the response to therapeutic agents.
肾上腺素能对免疫的调节作用已得到广泛研究,然而,关于多形核白细胞(PMN)的信息却很少,尽管它们在免疫和炎症中起着关键作用。我们研究了肾上腺素能药物对人PMN 迁移、CD11b 和 CD18 表达、活性氧物质(ROS)和白细胞介素(IL)-8 产生的影响,以及对肾上腺素能受体(AR)表达的影响。
通过 Boyden 室测定法测定迁移,通过流式细胞术测定 CD11b/CD18 表达,通过分光荧光法检测细胞内 ROS,通过标准 ELISA 测定法定量测定 IL-8。通过实时 PCR 测定 AR mRNA 水平,并通过扫描电子显微镜研究 PMN 形态。
肾上腺素(A)、去甲肾上腺素和β-AR 激动剂异丙肾上腺素减少了 N-甲酰基-Met-Leu-Phe(fMLP)诱导的迁移、CD11b/CD18 表达和 ROS 产生,但不影响 IL-8。A 对 CD11b 的作用被育亨宾和普萘洛尔拮抗,并被哌唑嗪增强。对 ROS 产生的作用被普萘洛尔完全阻断。PMN 表达 α(1A)-、α(1B)-、α(1D)-、α(2A)-、α(2C)-、β(1)-、β(2)-和β(3)-AR mRNA。A 防止了 fMLP 诱导的 PMN 形态变化。
肾上腺素能药物主要通过β-AR 减少 PMN 反应,尽管α-AR 至少对 CD11b 表达有贡献。在疾病状态和对治疗药物的反应中,应研究 AR 作用途径在 PMN 中的作用。